Financials data is unavailable for this security.
View more
Year on year Santen Pharmaceutical Co Ltd grew revenues 8.22% from 279.04bn to 301.97bn while net income improved from a loss of 14.95bn to a gain of 26.64bn.
Gross margin | 58.85% |
---|---|
Net profit margin | 8.84% |
Operating margin | 12.80% |
Return on assets | 6.32% |
---|---|
Return on equity | 8.84% |
Return on investment | 7.84% |
More ▼
Cash flow in JPYView more
In 2024, Santen Pharmaceutical Co Ltd increased its cash reserves by 63.35%, or 36.68bn. The company earned 72.65bn from its operations for a Cash Flow Margin of 24.06%. In addition the company used 6.15bn on investing activities and also paid 34.03bn in financing cash flows.
Cash flow per share | 126.98 |
---|---|
Price/Cash flow per share | 14.01 |
Book value per share | 862.32 |
---|---|
Tangible book value per share | 628.33 |
More ▼
Balance sheet in JPYView more
Current ratio | 2.60 |
---|---|
Quick ratio | 2.03 |
Total debt/total equity | 0.1905 |
---|---|
Total debt/total capital | 0.1604 |
More ▼
Growth rates in JPY
SmartText is unavailable
Div yield(5 year avg) | 2.18% |
---|---|
Div growth rate (5 year) | 4.88% |
Payout ratio (TTM) | 44.87% |
EPS growth(5 years) | -1.60 |
---|---|
EPS (TTM) vs TTM 1 year ago | 355.09 |
More ▼